Scinai Immunotherapeutics (SCNI) Non-Current Debt (2018 - 2026)

Scinai Immunotherapeutics has disclosed Non-Current Debt across 9 years of filings, most recently posting $285000.0 for Q2 2026.

• In Q2 2026, Non-Current Debt fell 2.73% year-over-year to $285000.0; the TTM figure through Jun 2026 stood at $285000.0 (down 2.73% YoY), while the FY2025 annual figure was $294000.0, up 13.08% from the prior year.
• Non-Current Debt came in at $285000.0 for Q2 2026 at Scinai Immunotherapeutics, down from $287000.0 in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $23.3 million in Q2 2023 to a low of $243000.0 in Q3 2022.
• Average Non-Current Debt over 5 years is $10.0 million, with a median of $5.3 million recorded in 2022.
• Year-over-year, Non-Current Debt tumbled 98.78% in 2022 and surged 7555.14% in 2023.
• Over 5 years, Non-Current Debt stood at $20.1 million in 2022, then slipped by 3.56% to $19.4 million in 2023, then slumped by 98.66% to $260000.0 in 2024, then advanced by 13.08% to $294000.0 in 2025, then retreated by 3.06% to $285000.0 in 2026.
• Per Business Quant data, the three most recent Non-Current Debt figures were $285000.0 in Q2 2026, $287000.0 in Q1 2026, and $294000.0 in Q4 2025.